This article was originally published in The Tan Sheet
Novartis has opened an OTC Research & Development center in Mumbai, India that is "currently working on various conventional and innovative dosage forms," the company announces Feb. 22. The center increases the firm's pharmaceutical development capacity by around 25%, the firm said. Novartis runs two other centers in Nyon, Switzerland and Lincoln, Neb. (1"The Tan Sheet" Oct. 21, 1996, p. 10). The facility will develop OTC drugs, including products for cough/cold, allergies, smoking cessation, gastrointestinal disorders, dermal infections and nutritional supplements. The center employs 35 associates, draws on the "expertise and skills" available in the country and "expands the company's presence in a country that is rapidly becoming a dominant force in the international marketplace," Novartis states...
You may also be interested in...
NOVARTIS SELF-MEDICATION MANUFACTURING WILL BE BASED IN LINCOLN, NEB. following the merger of Ciba-Geigy and Sandoz, the companies announced Oct. 17. The Sandoz manufacturing site in Lincoln will absorb the majority of the OTC production currently handled by Ciba's facility in Fort Washington, Pa.
Two European pharmaceutical companies, UCB and Merck KGaA, are exploring artificial intelligence in different ways, the first for drug discovery and the second on a fundamental level.
The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.